Non-small cell lung cancer

Indexed in Crossref

45 abstracts matching non-small cell lung cancer from the meeting's journal supplement, fetched live from Crossref 2026-11-12 09:23 UTC. This is a keyword search, not the complete abstract book.

• 343
  Functional assessment of autologous tumor-infiltrating lymphocytes in patient-matched 3D organoid models of non-small cell lung cancer

  David Graham, Daniel Nelson, Eric Struminger
• 403
  Differences in utilization of immune checkpoint inhibitors in individuals with advanced non-small cell lung cancer (NSCLC) by preexisting autoimmune disease

  Kerry A Conlin, Sarah Westvold, Xiao Wang, Pamela R Soulos et al.
• 71
  Spatial analysis of tumor microenvironment remodeling during non-small cell lung cancer progression

  Gaurav N Joshi, Nicholas Sciascia, Han Do, Thang Tran et al.
• 386
  Treatment patterns and real-world clinical outcomes with adjuvant pembrolizumab in resected patients with early-stage non-small cell lung cancer (eNSCLC)

  Shivanshu Awasthi, Pragya Rai, Yu-Han Kao, Ayman Samkari et al.
• 1193
  Analysis of a Phase II trial with GT103 in combination with pembrolizumab in refractory, advanced stage non–small cell lung cancer

  Frank Weinberg, Hirva Mamdani, James Herndon, Ryan Gentzler et al.
• 542
  A first-in-human phase 1/2 study of XTX501, a bispecific PD-1/masked IL-2, in metastatic non-small cell lung cancer (NSCLC)

  Myra W Popejoy, Benjamin Nicholson, Meghan Duncan, Scott McConnell et al.
• 538
  A phase 2/3 study of EIK1001 in combination with pembrolizumab and chemotherapy in participants with stage 4 non-small cell lung cancer (NSCLC) [TeLuRide-008]

  R Jotte, Dan Costin, M Gonzalez-Cao, J Remon et al.
• 316
  Enhancing NK cell immunotherapy in non-small cell lung cancer using dual-antigen tri-specific killer engager poly-antigen cytokine complexes (TriKE-PACCs)

  Rachel N Steinmetz, Shee Kwan Phung, Joshua Walker, Tumpa Dasgupta et al.
• 605
  Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)

  Ramaswamy Govindan, George R Blumenschein, Catherine Oakman, Meredith McKean et al.
• 99
  Host MHC heterozygosity is associated with favorable outcomes in surgically resected non-small cell lung cancer

  Jiyeon Jeon, Sung Wook Kang, Hee-Jin Jang, Ji Seon Shim et al.
• 488
  Phase I trial of GC101 TIL, a modified autologous tumor-infiltrating lymphocyte therapy, in advanced non-small cell lung cancer: long-term metabolic complete response in a patient with KRAS mutation

  Juan Li, Wenjia Zhuang, Shuwei Lin, Huajun Jin et al.
• 540
  Clinical trial of olvimulogene nanivacirepvec (olvi-vec), an oncolytic vaccinia virus-based immunotherapy, plus chemotherapy and an immune checkpoint inhibitor in non-small cell lung cancer (VIRO-25)

  Jason B Litten, Anita Seto, Terry Chamberlin, Shelby Hotopp et al.
• 1026
  A clinically interpretable recursive partitioning approach integrating clinical data and immune profiles for survival stratification in immune checkpoint inhibitor-treated non-small cell lung cancer

  Pauline K Patzke, Marietta Saldias-Montivero, Hannah G Stolrow, Jeffrey R Hage et al.
• 588
  Comparing treatment strategies in resectable non-small cell lung cancer: insights from multiple network meta-analysis approaches

  Tina Cascone, Jonathan D Spicer, Patrick M Forde, Nicholas Girard et al.
• 539
  A randomized, double-blind, phase III trial to compare SB27 (a proposed biosimilar to pembrolizumab) to reference pembrolizumab in participants with metastatic non-squamous non-small cell lung cancer

  Cengiz Karaçin, Jasuja Sandeep, Juan Carlos Vázquez Limón, Michael Schenker et al.
• 687
  Evolution of firstline treatment patterns and realworld efficacy of chemoimmunotherapy in extensivestage small cell lung cancer

  Xiaoyi Feng, Xiaoxing Gao, Xiaoyan Liu, Minjiang Chen et al.
• 1181
  Roginolisib plus dostarlimab with or without docetaxel reverts immune suppression and shows clinical activity in immunotherapy-resistant non-small cell lung cancer (NSCLC)

  Reinier Wener, Aitor Azkàrate Martínez, Alessandra Bearz, Angelo Delmonte et al.
• 368
  Association between obstructive sleep apnea and immune-mediated toxicity in patients with advanced melanoma and non-small cell lung cancer receiving immune checkpoint inhibitors in a real-world cohort

  Ethan Diamond, Olivia Wilkins, Georgios Stergiopoulos, Adil Alaoui et al.
• 1086
  Spatial transcriptomics resolves a dual CAF barrier to NK cell immunity in human lung adenocarcinoma

  Ana Nunez Cortes
• 218
  Delta-like ligand 3 (DLL3)-gated synNotch-CAR T-cells to overcome antigen heterogeneity in small cell lung cancer

  Celine J Prange, Javier Orozco Córdoba, Jaclyn Ng, Julien Sage et al.
• 318
  CAR-T and CAR-NK cell combination therapy targeting DLL3 or CD70 surface antigens promotes synergistic antitumor activity in small cell lung cancer

  Marco Campisi, Alan E Bers, Ian Gillanders, Eden Bobilev et al.
• 434
  Phenotypic state of circulating tumor-reactive T cells predict response to PD-1 blockade in non-small cell lung cancer

  Katsuhiro Ito, Kei Iida, Tomoko Hirano, Merrin Leong et al.
• 1007
  Clinical activity and immune effector toxicity patterns of tarlatamab in relapsed/refractory small cell lung cancer: a systematic review and meta-analysis

  Roshini Pasala, Rowan Bandaranaike, Sanad Alhushki, Mohammad Khaled Alhushki et al.
• 490
  Impact of radiation dose to the immune cells in extensive-stage small cell lung cancer in the immunotherapy era

  Zhipeng Li, Lehui Du, Yuting Zhao, Yi Wang et al.
• 633
  Preclinical evaluation of tumor treating fields (TTFields) applied alongside immunochemotherapy in non–small cell lung cancer

  Yiftah Barsheshet, Boris Brant, Tali Voloshin, Tal Kan et al.
• 487
  Efficacy and safety of consolidative thoracic radiotherapy in the era of immunotherapy for extensive-stage small cell lung cancer: a multicenter real-world study

  Zhipeng Li, Lehui Du, Yuting Zhao, Yi Wang et al.
• 489
  Prognostic value of inflammatory biomarkers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy combined with thoracic radiotherapy: a multicenter retrospective study

  Zhipeng Li, Lehui Du, Yuting Zhao, Yi Wang et al.
• 63
  Spatial cellular configuration indices predict outcomes following therapy in non-small cell lung carcinoma and melanoma

  Michael R Fotheringham, Benjamin Green, Jeffrey S Roskes, Nahid Moradi et al.
• 1145
  Spatial immunophenotyping reveals distinct myeloid and antigen-presenting cell networks in human lung cancer

  Leticia Montoya, Scott Clarke, Bhaskar Mandavilli, Anna Cartier
• 711
  Vaccination route programs qualitatively distinct dendritic cell activation states that shape anti-tumor CD8 T cell fate in ICB-resistant lung cancer

  Richard Van, Sebnem Gul, Grace Wolczanski, Fiona Chatterjee et al.
• 893
  JMB2302, a novel MUC16 × CD3 bispecific T cell engager, demonstrates potent antitumor activity in lung adenocarcinoma and ovarian cancer models and a favorable safety profile in cynomolgus monkeys

  Xiaodan Cao, Yanfang Gu, Jia Liu, Fu Zhou et al.
• 800
  Stromal-Derived IL-8 promotes M2 macrophage polarization via the RhoA/MRTF-A/SRF transcriptional axis to impair CD8 + T cell cytotoxicity in lung cancer

  Wentian Zhang, Jiang Lei
• 636
  A phase 2 study of Ateganosine in combination with ICI in patients with advanced non-small cell lung cancer resistant to prior ICI and chemotherapy: an exploratory analysis of LDH and survival

  Tomasz Jankowski, Veronika Muller, Saadettin Kilickap, Dan Lungulescu et al.
• 1090
  Remodeling of tertiary lymphoid structures during the preinvasive-to-invasive transition in lung adenocarcinoma provides a rationale for disease interception

  Liron Yoffe
• 1092
  Epithelial MHC II antigen diversity directs CD4 + resident T cell immunity in lung cancer

  Ezekiel Olumuyide, Miriam Saffern, Maame E Ackon, Prerna Suri et al.
• 802
  PPP1R14B influences prognosis and immunotherapy efficacy in lung adenocarcinoma by remodeling the tumor immune microenvironment

  Hongbo Li, Jie Zhang, Jingze Wang, Liliang Xia et al.
• 425
  A genomic mutation score integrating immune-context and literature-derived biomarkers predicts outcomes in ICI-treated lung adenocarcinoma

  Eman Elayeh, Lina Dahabiyeh, Shereen Aleidi, Yasser Bustanji
• 1094
  Disparities in immunotherapy use after FDA expansion among US patients with metastatic lung adenocarcinoma from 2014–2019

  Samay B Patel, Joel Jacob, Pranav Nedumpurath, Girindra Raval
• 41
  Peripheral blood immune kinetics during concurrent chemoradiation and durvalumab consolidation predict survival outcomes in lung cancer

  Sarina Tangyingyong, Kelvin Shi, Adrian Jones, Yaohua Ma et al.
• 428
  Targeting CXCR2 abrogates resistance to immune checkpoint blockade in Lkb1-mutant lung cancer via neutrophil reprogramming

  Tao Shi, Yunfeng Pan, Steven Chen, Cindy Chen et al.
• 665
  Optimizing KRAS G12C targeted therapy to enhance the efficacy of immunotherapy in lung cancer

  Mineyoshi Sato, Vincent Panneton, Valeria Estrada Navarro, Lauren Dong et al.
• 1091
  Spatially informing immune interception of squamous lung cancer

  Andrei Enica, Zoe Whiteman, Sam Gamble, Teerapon Sahwangarrom et al.
• 438
  Malignant cell transcriptional heterogeneity and immune escape genomics shape anti-PD1 responsiveness across NSCLC, HNSCC, and MIBC: a multi-modal single-cell and genomic analysis

  Ulrich Keilholz, Markus Eckstein, Stefan Florian, Krisztian Homicsko et al.
• 1131
  Near-real-time quantification of epithelial killing enables functional evaluation of T-cell engagers in fresh NSCLC tumors

  David Graham, Daniel Nelson, Eric Struminger
• 654
  On-treatment quantitative vessel tortuosity (QVT) score identifies severe vascular adverse event (SVAE) risk in non-squamous NSCLC: implications for VEGF inhibitor-PD-(L)1 combination

  Young K Chae, Rhea Chitalia, Kai Zhang, Liam Il-Young Chung et al.